The antiviral drug remdesivir does not reduce deaths among COVID-19 patients, as compared with standard care, according to the results of a large, international trial.
The Food and Drug Administration, in May, authorized remdesivir to be used in an emergency to treat COVID-19, after a large clinical trial suggested that the drug reduces the time it takes for COVID-19 patients to be discharged from the hospital, as compared with a placebo treatment, Live Science previously reported. As of August, the drug has been authorized for use in all patients hospitalized with COVID-19, not only those on supplemental oxygen, The New York Times reported. Thousands of U.S. patients have received the treatment, including the president.
But now, an enormous trial sponsored by the World Health Organization suggests that remdesivir doesn't reduce the risk of patients dying from COVID-19 in the month following treatment. The study was posted Oct. 15 to the preprint database medRxiv and has not yet been peer-reviewed; it included more than 11,200 people from 30 countries, The Times reported.
About 4,100 of those patients served as a comparison group and received no drug treatments, while the rest received one of four drugs, or a combination of several medications. These drugs included remdesivir, hydroxychloroquine, an antiviral called lopinavir and an immune-stimulating molecule called Interferon-β1a. About 650 patients received the interferon and lopinavir, together.
Ultimately, the study results suggest that no single drug or drug combination significantly reduced deaths among patients, as compared with the no-drug group. In addition, the drugs did not reduce the chances that treated patients would be placed on a ventilator, nor did the drugs reduce patients' time in the hospital.
"The unpromising overall findings from the regimens tested suffice to refute early hopes" that the medications would reduce mortality among COVID-19 patients, the study authors wrote. Earlier trials already indicated that hydroxychloroquine and lopinavir don't reduce mortality, but the data on remdesivir offers new insight on whether the drug really works, according to The Associated Press.
"The big story is the finding that remdesivir produces no meaningful impact on survival," Martin Landray, a professor of medicine and epidemiology at Oxford University, said in a statement, according to The Associated Press. However, Dr. Peter Chin-Hong, an infectious diseases expert at the University of California, San Francisco, told The New York Times that the trial results might be somewhat skewed.
The trial participants were treated at 405 different hospitals around the world, each with their own treatment protocols, so factors beyond remdesivir may have impacted patient survival, he noted. In addition, remdesivir may still offer benefit to patients if given early in the course of their illness, but that wasn't specifically addressed by the new study, Dr. Maricar Malinis, an infectious diseases physician at Yale University, told the Times.
But even if remdesivir helps some patients, it's still expensive and hard to administer, Landray said in a statement, according to the AP. "This is a drug that has to be given by intravenous infusion for five to 10 days," he said, noting it costs about $2,550 per treatment course. (The treatment course costs $3,120 for U.S. patients with private insurance, The Times reported.)
"COVID affects millions of people and their families around the world. We need scalable, affordable and equitable treatments," Landray said.
Originally published on Live Science.
Live Science newsletter
Stay up to date on the latest science news by signing up for our Essentials newsletter.
Nicoletta Lanese is the health channel editor at Live Science and was previously a news editor and staff writer at the site. She holds a graduate certificate in science communication from UC Santa Cruz and degrees in neuroscience and dance from the University of Florida. Her work has appeared in The Scientist, Science News, the Mercury News, Mongabay and Stanford Medicine Magazine, among other outlets. Based in NYC, she also remains heavily involved in dance and performs in local choreographers' work.
Do not believe anything coming from WHO. The FDA is on their own all caught up in financial bonuses. The WHO is ONLY about money.Reply
So WHO did a study on Remdisiver for a purpose for which it is not prescribed?Reply
Seems like a waste of money and not fit to be published.
And so what is your answer to this pandemic? Population destroying herd immunity? That leads to mass death.Trye said:Do not believe anything coming from WHO. The FDA is on their own all caught up in financial bonuses. The WHO is ONLY about money.
WHO isn't in the position to say anything. WHO has the same credibility of Chinese regime, ZERO. NO ONE cares about anything from WHO anymore, just like no one with a functioning brain cares or believes about Chinese statementsReply
The typical answer of a WHO burocRATjbundy48 said:And so what is your answer to this pandemic? Population destroying herd immunity? That leads to mass death.
Now LiveScience is the megaphone of WHO and Chinese regime propaganda. Time to unsubscribe.Reply
Jingles said:So WHO did a study on Remdisiver for a purpose for which it is not prescribed?
Seems like a waste of money and not fit to be published.
Non-experts in the U.S. Government pushed use of hydroxychloroquine to treat COVID-19, "for which it is not prescribed."
It was also a waste of money, but was fit to be published because hydroxychloroquine was killing people.
it's "bureaucRAT" You definitely need educating.EVpundit said:The typical answer of a WHO burocRAT
I was using a Soviet/Nazi Style word, "buro", anyway I am Italian, so, by any stardard, the fact I need more education related to a foreign language is a matter of fact. No problemjbundy48 said:it's "bureaucRAT" You definitely need educating.